Want to see CNSP full AI Analyst Report?
CNSP Stock Chart & Stats
$5.23
-$0.16(-3.06%)
At close: 4:00 PM EDT
$5.23
-$0.16(-3.06%)
Day’s Range― - ―
52-Week Range$1.90 - $10.59
Previous Close$5.1
Volume3.26K
Average Volume (3M)16.54K
Market Cap
$8.07M
Enterprise Value$12.70
Total Cash (Recent Filing)$19.98M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta3.26
Next Earnings
Nov 18, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-23.59
Shares Outstanding1,461,449
10 Day Avg. Volume15,052
30 Day Avg. Volume16,543
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.51
Price to Sales (P/S)0.00
P/FCF Ratio-0.17
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.04
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.65
Revenue Forecast (FY)$40.76M
Bulls Say, Bears Say
Bulls Say
Clinical TrialsTPI-287 demonstrated an overall response rate of 60% in a Phase 1 trial for rGBM, with a 96% disease control rate, indicating promising efficacy.
Regulatory ProspectsThe totality of data could support a formal discussion with the FDA around a potential filing or accelerated approval pathway for Berubicin without another trial.
Strategic DevelopmentCNS Pharmaceuticals is upgrading shares to Buy due to the pivot to its oncology asset TPI-287, which is in development for recurrent glioblastoma (rGBM).
Bears Say
Market PerformanceCNS Pharmaceuticals shares are at an all-time low due to the Berubicin trial missing its primary endpoint in March.
Trial ResultsBerubicin’s trial did not meet the primary OS endpoint, causing uncertainty about its effectiveness.
CNS Pharmaceuticals News
CNSP FAQ
What was CNS Pharmaceuticals’s price range in the past 12 months?
CNS Pharmaceuticals lowest stock price was $1.90 and its highest was $10.59 in the past 12 months.
What is CNS Pharmaceuticals’s market cap?
CNS Pharmaceuticals’s market cap is $8.07M.
When is CNS Pharmaceuticals’s upcoming earnings report date?
CNS Pharmaceuticals’s upcoming earnings report date is Nov 18, 2026 which is in 92 days.
How were CNS Pharmaceuticals’s earnings last quarter?
CNS Pharmaceuticals released its earnings results on Aug 12, 2026. The company reported -$0.38 earnings per share for the quarter, missing the consensus estimate of -$0.24 by -$0.14.
Is CNS Pharmaceuticals overvalued?
According to Wall Street analysts CNS Pharmaceuticals’s price is currently Overvalued.
Does CNS Pharmaceuticals pay dividends?
CNS Pharmaceuticals does not currently pay dividends.
What is CNS Pharmaceuticals’s EPS estimate?
CNS Pharmaceuticals’s EPS estimate is -0.27.
How many shares outstanding does CNS Pharmaceuticals have?
CNS Pharmaceuticals has 1,461,449 shares outstanding.
What happened to CNS Pharmaceuticals’s price movement after its last earnings report?
CNS Pharmaceuticals reported an EPS of -$0.38 in its last earnings report, missing expectations of -$0.24. Following the earnings report the stock price went down -8.893%.
Which hedge fund is a major shareholder of CNS Pharmaceuticals?
Currently, no hedge funds are holding shares in CNSP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CNS Pharmaceuticals
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.
Technical Analysis
Ownership Overview
26.02% Insiders
0.47% Mutual Funds
<0.01% Other Institutional Investors
73.02% Public Companies and
Individual Investors